Reminder for Phreesia Shareholder Class Action
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Source: Globenewswire
- Class Action Notice: Rosen Law Firm reminds investors who purchased Phreesia (NYSE: PHR) common stock between May 8, 2025, and March 30, 2026, to apply as lead plaintiffs by July 13, 2026, to participate in the class action and seek compensation.
- Lawsuit Background: The lawsuit alleges that defendants made false or misleading statements during the class period, concealing material adverse facts regarding Phreesia's slowing demand and reduced visibility in key revenue streams, resulting in investor losses when the truth emerged.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and recovered over $438 million for investors in 2019 alone, being ranked first by ISS Securities Class Action Services in 2017, demonstrating its expertise and success in this field.
- Participation Instructions: Investors can visit the Rosen Law Firm website or call the toll-free number for more information, ensuring they select qualified legal counsel to effectively represent them in the lawsuit and avoid inexperienced intermediaries.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PHR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PHR
Wall Street analysts forecast PHR stock price to rise
12 Analyst Rating
12 Buy
0 Hold
0 Sell
Strong Buy
Current: 9.050
Low
24.00
Averages
29.09
High
35.00
Current: 9.050
Low
24.00
Averages
29.09
High
35.00
About PHR
Phreesia, Inc. is a provider of comprehensive software solutions that improve the operational and financial performance of healthcare organizations. The Company's solutions include software-as-a-service (SaaS)-based integrated tools that manage patient access, registration, and payments. In addition, its solutions include clinical assessments to screen patients for a variety of physical, behavioral and mental health conditions, helping providers to understand their patients and connect them to needed services, resulting in improved health outcomes. Its Technology solutions segment provides life sciences companies, health plans and other payer organizations (payers), patient advocacy, public interest and other not-for-profit organizations with a channel for direct communication with patients. The Company's solutions also include additional products and services, such as the MediFind provider directory, which helps patients find care based on providers' specific clinical expertise.
About the author

Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
- Class Action Notice: Rosen Law Firm reminds investors who purchased Phreesia (NYSE: PHR) common stock between May 8, 2025, and March 30, 2026, to apply as lead plaintiffs by July 13, 2026, to participate in the class action and seek compensation.
- Lawsuit Background: The lawsuit alleges that defendants made false or misleading statements during the class period, concealing material adverse facts regarding Phreesia's slowing demand and reduced visibility in key revenue streams, resulting in investor losses when the truth emerged.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and recovered over $438 million for investors in 2019 alone, being ranked first by ISS Securities Class Action Services in 2017, demonstrating its expertise and success in this field.
- Participation Instructions: Investors can visit the Rosen Law Firm website or call the toll-free number for more information, ensuring they select qualified legal counsel to effectively represent them in the lawsuit and avoid inexperienced intermediaries.
See More
- Securities Fraud Investigation: Faruq & Faruq LLP is investigating potential securities fraud claims against Phreesia, Inc., alleging that the company and its executives made false and misleading statements from May 8, 2025, to March 30, 2026, causing investors to purchase securities at artificially inflated prices.
- Significant Stock Decline: Following the announcement on March 30, 2026, of drastically reduced revenue growth projections for fiscal year 2027, Phreesia's stock price plummeted from $11.41 to $8.38 per share, representing a decline of approximately 27%, resulting in substantial losses for investors.
- Legal Action Deadline: Investors must apply to become lead plaintiffs in the class action lawsuit by July 13, 2026, to represent other affected investors; those who do not apply can still participate as class members and share in any recovery.
- Encouragement for Whistleblowers: Faruq & Faruq LLP encourages anyone with information regarding Phreesia's conduct, including whistleblowers and former employees, to come forward to provide additional insights that could assist affected investors in obtaining compensation.
See More
- Class Action Reminder: The Schall Law Firm reminds investors of a class action lawsuit against Phreesia for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between May 8, 2025, and March 30, 2026, with a deadline to contact the firm by July 13, 2026.
- False Statements Allegation: The complaint alleges that Phreesia made false and misleading statements regarding its long-term growth outlook, claiming confidence in growth projections for fiscal year 2027 despite uncertainties that could jeopardize revenue targets, leading to investor losses.
- Legal Consultation Opportunity: The Schall Law Firm offers free consultations and encourages affected investors to act before the class is certified to ensure their rights are protected and avoid being absent class members.
- Market Reaction Impact: As the market learned the truth about Phreesia, investor losses intensified, indicating a lack of confidence in the company's growth commitments, which could negatively impact its future stock price.
See More
- Phreesia Lawsuit: Phreesia Inc. is accused of making false statements from May 8, 2025, to March 30, 2026, undermining investor confidence in its 2027 revenue targets, with a lead plaintiff deadline of July 13, 2026.
- Sportradar Violations: Sportradar Group AG faces allegations of collaborating with black-market gambling operators and failing to disclose compliance process weaknesses, with investors needing to file a lead plaintiff motion by July 17, 2026, potentially leading to significant financial repercussions.
- Commvault Sales Issues: Commvault Systems Inc. is accused of not disclosing the impact of sales types on annual recurring revenue (ARR) growth, with a lead plaintiff deadline of July 17, 2026, which could distort financial forecasts and investor expectations.
- Veritone Financial Misstatements: Veritone, Inc. is charged with inaccurately recording revenue and costs, necessitating a restatement of financial statements, with a lead plaintiff deadline of July 20, 2026, which may harm the company's reputation and shareholder confidence.
See More
- Class Action Filed: A class action lawsuit has been initiated against Phreesia, Inc. (NYSE:PHR) by shareholders who purchased securities between May 8, 2025, and March 30, 2026, due to the company's failure to disclose deteriorating pharmaceutical marketing commitments, highlighting a significant gap between internal knowledge and public disclosures.
- Stock Price Plunge: Following the revelation on March 30, 2026, that pharmaceutical manufacturers were committing far less than anticipated, Phreesia's stock price fell by $3.03, representing a 27% decline, which directly impacted investor confidence and the company's market capitalization.
- Discrepancy in Information: The lawsuit alleges that Phreesia's management had ongoing access to critical pharmaceutical marketing commitment data throughout the class period but publicly maintained that spending patterns remained consistent with previous years, leading investors to purchase shares at artificially inflated prices.
- Legal Implications and Investor Protection: The filing of this lawsuit raises important questions about the timing of internal risk awareness versus public disclosures, with investors needing to submit claims by July 13, 2026, to protect their rights, underscoring the need for improved corporate governance and transparency.
See More
- Class Action Notice: Rosen Law Firm reminds investors who purchased Phreesia (NYSE: PHR) common stock between May 8, 2025, and March 30, 2026, to apply as lead plaintiffs by July 13, 2026, to participate in the class action and seek compensation.
- Fee Arrangement: Investors joining the class action will incur no upfront costs, as the law firm operates on a contingency fee basis, allowing investors to pursue claims without financial burden.
- Lawsuit Background: The lawsuit alleges that Phreesia made false or misleading statements during the class period, concealing adverse facts such as weakened pharmaceutical marketing commitments in its Network Solutions segment, resulting in investor losses when the truth emerged.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions, having recovered over $438 million for investors in 2019 alone, and was ranked first in 2017 for the number of securities class action settlements, demonstrating its expertise and success in this field.
See More







